- Home
- DGICB vs CTNM Comparison
DGICB vs CTNM Comparison
Compare DGICB & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGICB
- CTNM
- Stock Information
- Founded
- DGICB 1986
- CTNM 2009
- Country
- DGICB United States
- CTNM United States
- Employees
- DGICB N/A
- CTNM N/A
- Industry
- DGICB Property-Casualty Insurers
- CTNM
- Sector
- DGICB Finance
- CTNM
- Exchange
- DGICB Nasdaq
- CTNM Nasdaq
- Market Cap
- DGICB 431.9M
- CTNM 453.0M
- IPO Year
- DGICB N/A
- CTNM 2024
- Fundamental
- Price
- DGICB $14.11
- CTNM $17.21
- Analyst Decision
- DGICB
- CTNM Strong Buy
- Analyst Count
- DGICB 0
- CTNM 4
- Target Price
- DGICB N/A
- CTNM $29.25
- AVG Volume (30 Days)
- DGICB 392.0
- CTNM 74.8K
- Earning Date
- DGICB 10-24-2024
- CTNM 11-06-2024
- Dividend Yield
- DGICB 4.39%
- CTNM N/A
- EPS Growth
- DGICB 148.60
- CTNM N/A
- EPS
- DGICB 0.74
- CTNM N/A
- Revenue
- DGICB $979,119,004.00
- CTNM N/A
- Revenue This Year
- DGICB N/A
- CTNM N/A
- Revenue Next Year
- DGICB $6.66
- CTNM N/A
- P/E Ratio
- DGICB $21.13
- CTNM N/A
- Revenue Growth
- DGICB 7.44
- CTNM N/A
- 52 Week Low
- DGICB $10.75
- CTNM $13.27
- 52 Week High
- DGICB $16.00
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- DGICB 52.01
- CTNM N/A
- Support Level
- DGICB $13.34
- CTNM N/A
- Resistance Level
- DGICB $14.90
- CTNM N/A
- Average True Range (ATR)
- DGICB 0.11
- CTNM 0.00
- MACD
- DGICB -0.02
- CTNM 0.00
- Stochastic Oscillator
- DGICB 49.28
- CTNM 0.00
About DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.